http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014143639-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014143639-A |
| titleOfInvention | ADJUSTABLE PROTEASIS ANTIBODIES |
| abstract | 1. A protease-regulated antibody that specifically binds to a tissue factor pathway inhibitor (TFPI) that includes a variable domain, a constant domain, and an amino acid sequence connecting the variable domain to a constant domain, where the amino acid sequence includes a protease cleavage site. The protease-regulated antibody of claim 1, wherein the protease cleavage site is a thrombin cleavage site. The protease-regulated antibody of claim 1, wherein the protease cleavage site is a plasmin cleavage site. The protease-regulated antibody of claim 1, wherein the protease cleavage site is a Factor Xa.5 cleavage site. The protease-regulated antibody of claim 1, which comprises an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO: 131, amino acids 1-239 of the sequence SEQ ID NO: 133, SEQ ID NO: 135, amino acids 1-229 of the SEQ sequence ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 143 and SEQ ID NO: 144.6. Protease-regulated antibody according to any one of paragraphs. 1-5, where the amino acid sequence further includes an amino acid linker. 7. Protease-regulated antibody according to any one of paragraphs. 1-5, which is a full-length antibody. 8. Protease-regulated antibody according to any one of paragraphs. 1-5, which is an antibody fragment. 9. A pharmaceutical composition that comprises a protease-regulated antibody according to any one of claims. 1-8 and a pharmaceutically acceptable carrier. 10. An isolated nucleic acid molecule encoding a protease-regulated antibody according to any one of claims. 1-8.11. A method for treating coagulopathy, which comprises administering to a patient in need thereof a therapeutically effective amount |
| priorityDate | 2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.